These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28975475)

  • 21. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.
    Kao DP; Wagner BD; Robertson AD; Bristow MR; Lowes BD
    PLoS One; 2012; 7(11):e48184. PubMed ID: 23144856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.
    Verma A; Kalman JM; Callans DJ
    Circulation; 2017 Apr; 135(16):1547-1563. PubMed ID: 28416525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction.
    Abi Khalil C; Zubaid M; Asaad N; Rashed WA; Hamad AK; Singh R; Al Suwaidi J
    Angiology; 2018 Apr; 69(4):316-322. PubMed ID: 28737070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure With Reduced Ejection Fraction.
    Lam PH; Keramida K; Filippatos GS; Gupta N; Faselis C; Deedwania P; George B; Iskandrian A; Cleland JG; Choudhary G; Wu WC; Morgan CJ; Fonarow GC; Ahmed A
    J Card Fail; 2022 Jan; 28(1):65-70. PubMed ID: 34419597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation.
    Ahn MS; Yoo BS; Son JW; Yu MH; Kang DR; Lee HY; Jeon ES; Kim JJ; Chae SC; Baek SH; Kang SM; Choi DJ; Kim KH; Cho MC; Kim SY
    J Korean Med Sci; 2020 Aug; 35(33):e278. PubMed ID: 32830467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
    Bristow MR; Murphy GA; Krause-Steinrauf H; Anderson JL; Carlquist JF; Thaneemit-Chen S; Krishnan V; Abraham WT; Lowes BD; Port JD; Davis GW; Lazzeroni LC; Robertson AD; Lavori PW; Liggett SB
    Circ Heart Fail; 2010 Jan; 3(1):21-8. PubMed ID: 19880803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.
    Taylor MR; Slavov D; Humphrey K; Zhao L; Cockroft J; Zhu X; Lavori P; Bristow MR; Mestroni L; Lazzeroni LC
    Pharmacogenet Genomics; 2009 Jan; 19(1):35-43. PubMed ID: 18953265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of heart rate in elderly with systolic heart failure and concomitant atrial fibrillation.
    Barywani S; Petzold M
    Scand Cardiovasc J; 2017 Aug; 51(4):190-196. PubMed ID: 28393567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
    Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
    Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bucindolol: new hopes from reviewing past data.
    Fiuzat M; O'Connor CM
    Drugs Today (Barc); 2011 May; 47(5):347-51. PubMed ID: 22013565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.
    Lalukota K; Cleland JG; Ingle L; Clark AL; Coletta AP
    Eur J Heart Fail; 2004 Dec; 6(7):953-5. PubMed ID: 15556058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New-onset atrial fibrillation predicts heart failure progression.
    Aleong RG; Sauer WH; Davis G; Bristow MR
    Am J Med; 2014 Oct; 127(10):963-71. PubMed ID: 24931393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.
    Rienstra M; Damman K; Mulder BA; Van Gelder IC; McMurray JJ; Van Veldhuisen DJ
    JACC Heart Fail; 2013 Feb; 1(1):21-8. PubMed ID: 24621795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions.
    Grubb A; Mentz RJ
    Expert Rev Cardiovasc Ther; 2020 Feb; 18(2):85-101. PubMed ID: 32066285
    [No Abstract]   [Full Text] [Related]  

  • 37. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.
    Zoghi M; Kaya H; Çavuşoğlu Y; Aksakal E; Demir Ş; Yücel C; Mutlu H; Ergene O; Yılmaz MB;
    Turk Kardiyol Dern Ars; 2016 Sep; 44(6):457-65. PubMed ID: 27665326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of beta-blocker therapy in heart failure and atrial fibrillation.
    Fung JW; Yu CM; Kum LC; Yip GW; Sanderson JE
    Card Electrophysiol Rev; 2003 Sep; 7(3):236-42. PubMed ID: 14739721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study.
    Nielsen PB; Larsen TB; Gorst-Rasmussen A; Skjøth F; Lip GY
    Circ Heart Fail; 2016 Feb; 9(2):e002597. PubMed ID: 26823497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.
    Lymperopoulos A; Negussie S; Walklett K
    Pharmacogenomics; 2013 Oct; 14(13):1545-9. PubMed ID: 24088125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.